---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-23-000133"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:07:30.187590+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio Q3 net loss $40M, cash sufficient into H1 2026; PROSERA study ahead

## Summary
- Net loss $40.0M ($0.21/share) vs $59.4M loss in Q3 2022; R&D expenses $31.2M (down from $44.5M).
- Cash, equivalents & marketable securities $328.9M; expected to fund operations into first half of 2026.
- Phase 3 PROSERA site activations ahead of schedule; first patient dosing expected in Q4 2023.
- Additional TORREY open-label extension data (seralutinib in PAH) expected in Q4 2023.
- FRI sub-study of TORREY presented at ERS 2023; evidence of improved pulmonary blood vessel volume.

## SEC filing metadata
- accession: 0001728117-23-000133
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/0001728117-23-000133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/goss-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-23-000133
- JSON: https://secwatch.observer/filing/0001728117-23-000133.json
- Plain text: https://secwatch.observer/filing/0001728117-23-000133.txt

## Key facts
- Earnings Releases
  Gossamer Bio, Inc. reported third quarter ended September 30, 2023 results: net income $40.0 million, or $0.21 per share, EPS $0.21 per share.
  - Period: third quarter ended September 30, 2023
  - Net income: $40.0 million, or $0.21 per share
  - EPS: $0.21 per share
  - Result: reported results
  source text: Net loss for the quarter ended September 30, 2023, was $40.0 million, or $0.21 per share, compared to a net loss of $59.4 million, or $0.65 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1728117/000172811723000133/0001728117-23-000133-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.